

(51) International Patent Classification:

C07K 16/46 (2006.01) *C07K 16/28* (2006.01)
C07K 1/113 (2006.01) *C12N 15/13* (2006.01)

(21) International Application Number:

PCT/JP2021/013795

(22) International Filing Date:

31 March 2021 (31.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2020-062601 31 March 2020 (31.03.2020) JP

(71) Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
[JP/JP]; 5-1, Ukima 5-chome, Kita-ku, Tokyo, 1158543 (JP).

(72) Inventors: CHICHILI, Vishnu Priyanka Reddy; c/o Chugai Pharmabody Research Pte. Ltd., 3, Biopolis Drive, #07-11 to 16 Synapse, 138623 (SG). PANG, Chai Ling; c/o


Chugai Pharmabody Research Pte. Ltd., 3, Biopolis Drive, #07-11 to 16 Synapse, 138623 (SG). **KAWA, Tatsuya**; c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 135, Komakado 1-chome, Gotemba-shi, Shizuoka, 4128513 (JP). **FENG, Shu**; c/o Chugai Pharmabody Research Pte. Ltd., 3, Biopolis Drive, #07-11 to 16 Synapse, 138623 (SG). **GAN, Siok Wan**; c/o Chugai Pharmabody Research Pte. Ltd., 3, Biopolis Drive, #07-11 to 16 Synapse, 138623 (SG). **TAKAHASHI, Noriyuki**; c/o Chugai Pharmabody Research Pte. Ltd., 3, Biopolis Drive, #07-11 to 16 Synapse, 138623 (SG). **MURAOKA, Masaru**; c/o CHUGAI SEIYAKU KABUSHIKI KAISHA, 135, Komakado 1-chome, Gotemba-shi, Shizuoka, 4128513 (JP).

(74) Agent: HARUNA, Masao et al.; Kantetsu Tsukuba Bldg. 6F, 1-1-1, Oroshi-machi, Tsuchiura-shi, Ibaraki, 3000847 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

(54) Title: METHOD FOR PRODUCING MULTISPECIFIC ANTIGEN-BINDING MOLECULES

[Fig. 1]



(57) **Abstract:** Multispecific antigen-binding molecule capable of binding to multiple different antigens, but do not non-specifically crosslink two or more immune cells such as T cells are provided. Methods for producing or enriching a preferred structural form of such multispecific antibody protein, and method for eliminating disulfide heterogeneity of such multispecific antibody proteins are provided. In addition, conformation-specific antibodies that specifically recognize the preferred form of multispecific antibody proteins, and use of the conformation-specific antibodies are provided.

[Continued on next page]

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*